The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.
The physiologic mechanisms mediating the glucose-lowering effect of Roux-en-Y Gastric Bypass (RYGB) or post-Vertical Sleeve Gastrectomy (VSG) are unknown. The reduction in glucose excursions prior to weight loss has lead to postulates that the incretin hormone, GLP-1, may play an important role. The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions in a subset of post-bariatric patients through the pharmacologic blockade of the GLP-1 receptor in post-RYGB or post-VSG patients with severe symptomatic hypoglycemia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
10
IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
Stanford University School of Medicine
Stanford, California, United States
Plasma glucose area under the curve
Time frame: 0 to 180 minutes
Plasma insulin area under the curve
Time frame: 0 to 180 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.